



3rd European Workshop on

## Skin immune mediated inflammatory diseases (SIMID)

from September 24th 2020 to March 24th 2021



#### **Chairmen:**

Giampiero Girolomoni, Verona Lluís Puig, Barcelona

#### **Scientific Secretariat:**

Paolo Gisondi. Verona

#### **Scientific Committee:**

H. Bachelez, Paris

S. Beissert, *Dresden* 

M. de Rie. Amsterdam

M. Gilliet, Lausanne

J. Ingram, Cardiff

J. Lambert, Ghent

A.V. Marzano, Milan

K. Papp, Waterloo

C. Traidl-Hoffmann, Munich

## **FINAL PROGRAM**

www.simid2020.org



## Welcome to the new digital SIMID

Dear Colleagues and Friends,

We are very pleased to welcome you at the 3<sup>rd</sup> European Workshop on Skin Immune Mediated Inflammatory Diseases (Digital SIMID).

The Workshop is aimed to comprehensively discuss SIMID from basic mechanisms to therapy.

Specifically, the Workshop wants to emphasize a discussion, which drives new research on common pathogenetic pathways and on the use of new anti-inflammatory and immunoregulatory drugs.

Inflammatory and immune-mediated diseases have a great prevalence and relevance to general medicine and dermatology.

Pathways common to different diseases are being elucidated and many new treatment options are becoming available, increasing the need of forums where basic, translational and clinical research are presented together.

In consideration of the ongoing COVID-19 outbreak, the 3<sup>rd</sup> SIMID Workshop has been converted into a Digital meeting.

Therefore, the meeting will be held in a digital web platform where registered people will have the possibility to watch lectures, download the presentations and directly ask questions or make comments to the lecturers. Italian ECM credits will be provided.

Kindest Regards,



Giampiero Girolomoni



Lluís Puig



Paolo Gisondi





## Registration

The e-learning material of DIGITAL SIMID will be available on Ecliptica's e-learning platform from September 24<sup>th</sup> 2020 to March 24<sup>th</sup> 2021 and will be constituted by pre-recorded presentations.

#### How to access to the platform and join the digital SIMID

In order to access to the platform for the first time, you need to register by creating an account: you will be asked to choose a username and a password that you will need it every time you want to log in. An automatic e-mail will be sent to your email address; click on the link to confirm your e-learning platform account. Once you have logged to the e-learning platform, you will have access to all the Ecliptica e-learning courses.

To start DIGITAL SIMID, it is necessary to sign in: just click on the course title to see the registration fee and methods of payment. Once you are signed in you'll be authorized to start the course!

### **Registration fees**

Delegates	305,00 €	(VAT 22% included)
Residents / Students	122,00 €	(VAT 22% included)

### **Registration fees includes**

- Admission to the e-learning materials;
- · Possibility to collect Italian Credit after participation to scientific sessions;
- Certificate of Attendance.



### **General Information**

#### Italian ECM accreditation

The DIGITAL SIMID is accredited by the Italian Ministry of Health for Italian physicians for a maximum of 400 participants.

13 ECM Credits.

#### **Abstracts**

The Scientific Committee invites authors to submit their abstracts for consideration and inclusion in the e-learning materials of DIGITAL SIMID as e-poster.

Abstract submission deadline has been posponed to November 30th.

Please check the rules and send your abstract at:

http://www.simid2020.org/abstract.php



## Scientific Program

#### Welcome introduction, G. Girolomoni (Verona), L. Puig (Barcelona)

- 1. Langerhans cells and dendritic cells in skin immunity, G. Stingl (Vienna)
- 2. Autoreactive T-lymphocytes in skin diseases, W.H. Boehncke (Geneva)
- 3. Skin-microbe interaction as a function of skin homeostasis C. Traidl-Hoffmann (Munich)
- 4. Neutrophilic dermatoses, A.V. Marzano (Milan)
- **5. Eosinophilic dermatoses,** *D. Simon (Bern)*
- 6. Panniculitis: black beast of dermatologists and dermatopathologists *F. Rongioletti (Cagliari)*
- 7. Vasculitis syndromes, C. Sunderkotter (Halle)
- 8. Lupus erythematosus, M. Mosca (Pisa)
- 9. Oral lichen planus, M. Carrozzo (Newcastle)
- 10. Vitiligo, M. Picardo (Rome)
- 11. Alopecia areata, A. Taieb (Bordeaux)
- 12. Efficacy and safety of tildrakizumab in the treatment of patients with psoriasis, S. Piaserico (Padua)
- **13.** Efficacy and safety of risankizumab in the treatment of patients with psoriasis, *G. Argenziano (Naples)*
- **14.** Place in therapy of apremilast in the treatment of patients with psoriasis *M.T. Rossi (Brescia)*
- **15.** Psoriasis: patient education, *J. Lambert (Ghent)*
- 16. Efficacy and safety of brodalumab in the treatment of patients with psoriasis, A. Conti (Modena)
- 17. The complete treatment of plaque psoriasis, P. Gisondi (Verona)



## Scientific Program

- **18.** Treatment of nail psoriasis, F. Bardazzi (Bologna)
- 19. Pustular psoriasis, H. Bachelez (Paris)
- 20. Management strategies for patients with psoriasis during the COVID-19 pandemic, *P. Gisondi (Verona)*
- **21.** Pemphigoids, G. Zambruno (Rome)
- **22.** Pemphigus, M. Hertl (Marburg)
- 23. Hidradenitis suppurativa: an update on multidisciplinary management J. Ingram (Cardiff)
- 24. Urticaria, M. Metz (Berlin)
- 25. Cutaneous drug reactions, M. Mockenhaupt (Freiburg)
- **26.** Non infective cutaneous granulomatous diseases, R. Cerio (London)
- **27.** Itch: from new mediators to new treatments, *S. Stander (Munster)*
- **28.** Discovering the science in type-2 inflammation, *A. Matucci (Florence)*
- 29. Atopic dermatitis: charting the new therapeutic frontier, L. Puig (Barcelona)
- **30.** Dupilumab in the treatment of atopic dermatitis, G. Girolomoni (Verona)
- 31. Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: a perspective from China, Q. Lu (Hunan)
- **32.** Guselkumab: a holistic approach in the treatment of psoriatic disease *L. Naldi (Vicenza)*



# Organizers are proud to thank for contributing the following sponsorship:

























Organizing Secretariat:





